EPP afamelanotide trial gave Mr. Willis hours of sun tolerance

During a double-blind afamelanotide study, EPP patient Mr. Willis estimated “a couple of hours before symptoms began,” compared with 5 to 10 minutes of tingling, burning, and itching without treatment. The report centers on one patient’s experience rather than cohort efficacy results.

Mr. Willis and Dr. Bonkovsky traced those lessons in the Dermatology Times episode “EPP Patient Journey: Trial Experience, IV Iron Risk, and Emotional Burden.” Their conversation covered his first trial, the reason he avoided intravenous iron, and the emotional weight of living with EPP.

What did the first afamelanotide trial show?

The study used a double-blind design. Mr. Willis nevertheless became noticeably more pigmented, which Dr. Bonkovsky said suggested that he had taken active drug. Blinding becomes difficult when a drug changes pigmentation.

Dr. Bonkovsky began by asking how much improvement Mr. Willis had noticed. The pigmentation change supplied the practical clue to his treatment assignment.

He tolerated the implants well. He described a few days of discomfort that felt like a bruise. Mr. Willis also said he held back because he was only a few years past his liver crisis.

The practical gain was time. He could travel to Africa without worrying as much about covering up. During the study, he estimated that symptoms began after a couple of hours rather than the 5 to 10 minutes he had managed without treatment.

That difference stretched his symptom-free interval from minutes to hours, turning a daily constraint into a travel experience that required less covering up.

Takeaway: The first trial gave Mr. Willis hours of tolerance and easier travel, but his sun tolerance reverted after the study.

Why was intravenous iron avoided in classical EPP?

Mr. Willis had not received intravenous iron again. His caution followed a specific warning from Dr. Bonkovsky: mild iron deficiency is common in EPP, but intravenous iron carries a substantial risk of acute worsening in classical disease.

Dr. Bonkovsky advised against intravenous iron, calling it strongly contraindicated. The potential consequences include severe photosensitivity and liver complications. He said slower oral iron is safer.

He contrasted that risk with X-linked protoporphyria. In the latter, he said, iron replacement tends to improve the disorder rather than trigger an acute worsening.

Diagnostic practice has also shifted. Dr. Bonkovsky said clinicians no longer need an iron tolerance test because biochemical and genetic testing are far better tools.

Takeaway: In classical EPP, slower oral iron is safer, while intravenous iron can sharply worsen disease.

What burden remains after the trial?

After the study, Mr. Willis returned to covering up. He described spending almost a month in the dark after reactions to ambient light and light bulbs. The trial’s gains in sun tolerance did not erase that vigilance.

Mr. Willis said the emotional burden of EPP is seldom discussed. He described a constant fear of “hidden light sources,” even in a restaurant far from windows.

Precautions cannot identify every source. A patient can take every precaution and still encounter light that provokes a reaction. Mr. Willis also said some reactions are worse than others.

The restaurant example shows the uncertainty. Even a familiar indoor setting may contain an unnoticed light source that the patient cannot prepare for in advance.

Takeaway: Sun protection helps, but unpredictable light exposure leaves EPP patients watching their surroundings.

What comes next in Mr. Willis’s treatment journey?

The next episode, “EPP Patient Journey: Oral Therapies and Regaining Freedom in the Sun,” follows Mr. Willis through two more trials. It also follows the treatment he says changed his life.

The forthcoming chapter moves beyond the first implant study. It places two more trials and oral therapies in sequence, with the treatment Mr. Willis credits with changing his life as the series’ focus.

Takeaway: The series next follows two more trials and a treatment Mr. Willis says changed his life.